48 lawsuits against Brilinta patent only in 15 days

Generics of Brilinta(AstraZeneca, ticagrelor), which has been recognized as a next-generation  antithrombotic agent followed by Aspirin and Plavix, have attracted vigorous interests of domestic pharmaceutical companies.

A number of companies have joined in the patent lawsuit, in particular, as saying an exclusive sales license of the large product cannot be missed.

According to the pharmaceut...